Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019043201) TRANSCRIPTION FACTOR ZNF471 AS A THERAPEUTIC AGENT AND A BIOMARKER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/043201 International Application No.: PCT/EP2018/073545
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
C07K 14/47 (2006.01) ,A61P 9/10 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
46
from vertebrates
47
from mammals
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9
Drugs for disorders of the cardiovascular system
10
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applicants:
SORBONNE UNIVERSITE [FR/FR]; 21 rue de l' Ecole de Médecine 75006 Paris, FR
INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) [FR/FR]; 101 rue de Tolbiac 75013 PARIS, FR
ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS [FR/FR]; 3 avenue Victoria 75004 PARIS, FR
Inventors:
LE GOFF, Wilfried; FR
TREGOUET, David-Alexandre; FR
CARRIE, Alain; FR
COUVERT, Philippe; FR
Agent:
CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand 75002 PARIS, FR
Priority Data:
17306129.201.09.2017EP
Title (EN) TRANSCRIPTION FACTOR ZNF471 AS A THERAPEUTIC AGENT AND A BIOMARKER
(FR) FACTEUR DE TRANSCRIPTION ZNF471 UTILISÉ EN TANT QU'AGENT THÉRAPEUTIQUE ET BIOMARQUEUR
Abstract:
(EN) The present invention relates to the identification of Transcription Factor ZNF471 as a therapeutic agent and a biomarker in the field of dyslipidemia. In one aspect, the invention thus relates to therapeutic uses of ZNF471. In another aspect, the invention relates to diagnostic methods based on detecting alterations in the ZNF471 gene locus.
(FR) La présente invention concerne l'identification du facteur de transcription ZNF471 en tant qu'agent thérapeutique et biomarqueur dans le domaine de la dyslipidémie. Selon un aspect, l'invention concerne des utilisations thérapeutiques de ZNF471. Selon un autre aspect, l'invention concerne des procédés de diagnostic basés sur la détection d'altérations dans le locus du gène ZNF471.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)